Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display - Cocktail

605 - NORTH/HGCSG1003 : A phase II study evaluating the safety and efficacy of FOLFOX as adjuvant chemotherapy for patients with stage III colon cancer : Comparison with medical oncologists and surgeons.


24 Nov 2018


Poster display - Cocktail


Tumour Site

Colon and Rectal Cancer


Ichiro Iwanaga


Annals of Oncology (2018) 29 (suppl_9): ix28-ix45. 10.1093/annonc/mdy431


I. Iwanaga1, S. Yuki2, Y. Kawamoto2, H. Nakatsumi3, N. Takahashi4, T. Shichinohe5, H. Okuda6, A. Ishiguro7, K. Harada8, K. Hatanaka9, K. Oomori10, M. Nakamura11, N. Senmaru12, K. Iwai13, M. Koike14, Y.M. Ito15, A. Taketomi16, S. Hirano5, N. Sakamoto2, Y. Komatsu3

Author affiliations

  • 1 Medical Oncology, Japanese Red Cross Kitami Hospital, 090-8666 - Kitami/JP
  • 2 Gastroenterology And Hepatology, Hokkaido University Hospital, 060-8638 - Sapporo/JP
  • 3 Cancer Center, Hokkaido University Hospital, 060-8638 - Sapporo/JP
  • 4 Surgical Center, Hokkaido University Hospital, 060-8638 - Sapporo/JP
  • 5 Gastroenterological Surgery Ii, Hokkaido University Hospital, 060-8638 - Sapporo/JP
  • 6 Medical Oncology, Keiyukai Sapporo Hospital, 003-0027 - Sapporo/JP
  • 7 Medical Oncology, Teine Keijinkai Hospital, 006-8555 - Sapporo/JP
  • 8 Medical Oncology, Kushiro Rosai Hospital, Kushiro/JP
  • 9 Gastroenterology, Hakodate Municipal Hospital, 041-8680 - Hakodate/JP
  • 10 Surgery, Keiwakai Ebetsu Hospital, Ebetsu/JP
  • 11 Gastroenterology, Sapporo City General Hospital, 060-8604 - Sapporo/JP
  • 12 Surgery, Steel Memorial Muroran Hospital, Muroran/JP
  • 13 Surgery, Oji General Hospital, Tomakomai/JP
  • 14 Surgery, KKR Sapporo Medical Center, Sapporo/JP
  • 15 Biostatistics, Hokkaido University Graduate School of Medicine, Sapporo/JP
  • 16 Gastroenterological Surgery I, Hokkaido University Hospital, 060-8638 - Sapporo/JP


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 605


The efficacy of oxaliplatin containing regimens were confirmed in large randomized phase III trials in which they were superior to fluorouracil and leucovorin as adjuvant setting for patients with stage III colon cancer. In Japan, not only medical oncologists but also surgeons practice chemotherapy. In this analysis, we investigated differences in safety and efficacy between surgeons and medical oncologists from NORTH/HGCSG1003 study.


NORTH/HGCSG1003 is a multicenter phase II study. This study enrolled patients with resected stage III colon cancer. Patients received FOLFOX4 or mFOLFOX6 repeated every 2 weeks for 12 cycles. Primary endpoint is disease-free survival, and secondary endpoints were overall survival, safety, RDI and so on. In this analysis, pts characteristics and safety were compared using Fisher’s exact test. Dose intensity was compared using Student's t-test, and DFS and RFS using log-rank test.


From September 2010 to March 2013, 273 patients at 28 institutions were enrolled. In the eligible population (n = 264), 159 patients were treated with chemotherapy by medical oncologists (group O) and 105 patients by surgeons (group S). Patients’ characteristics between two groups were well balanced except for bowel obstruction before surgery (8.8 % in group O vs 23.8% in group S; p = 0.001). Median RDI (group O vs group S) of oxaliplatin was 0.631 vs 0.751 (p < 0.001) and that of bolus 5-FU was 0.638 vs 0.797 (p < 0.001). The difference in completion treatment rate of 12 cycles between two group was not statistically significant (83.6% vs 76.2%; p = 0.153). 3y DFS rate was 75.3% in group O and 74.9% in group S (HR 0.976, p = 0.919). 3y RFS rate was 75.9% in group O and 78.8% in group S (HR 0.888, p = 0.643).


RDI of oxaliplatin and bolus 5-FU were significantly lower in group O than group S. The frequency of platelet count decreased (all grade) was significantly less in O. This was presumed to be because the RDI of oxaliplatin was significantly lower in O. However, there was no significant difference in the frequency of peripheral sensory neuropathy. There was no significant difference in efficacy between O and S.

Editorial acknowledgement

Clinical trial identification

UMIN000004590, 2011/01/15.

Legal entity responsible for the study

Non-profit Organization: Hokkaido Gastrointestinal Cancer Study Group.


Non-profit Organization: Hokkaido Gastrointestinal Cancer Study Group.


S. Yuki: Honoraria: Yakult Honsha Co., Ltd. Y. Komatsu: Research Funding Yakult Honsha Co., Ltd. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.